BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iioka F, Shimomura D, Ishii T, Maesako Y, Ohgoe K, Nakamura F, Matsuo S, Ohno H. Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports. Int J Hematol 2012;96:506-12. [PMID: 22878941 DOI: 10.1007/s12185-012-1162-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Iioka F, Tsuda K, Shimomura D, Nakagawa M, Okumura A, Hayashida M, Izumi K, Kamoda Y, Akasaka T, Ohno H. Schistocytosis in acute myeloid leukemia with myelodysplasia-related changes, showing predominant erythroid proliferation. Tenri Med Bull 2015;18:42-50. [DOI: 10.12936/tenrikiyo.18-014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Schaller M, Studt J, Voorberg J, Hovinga JA. Acquired thrombotic thrombocytopenic purpura: Development of an autoimmune response. Hamostaseologie 2018;33:121-30. [DOI: 10.5482/hamo-12-12-0023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
3 Matsumoto T, Fan X, Ishikawa E, Ito M, Amano K, Toyoda H, Komada Y, Ohishi K, Katayama N, Yoshida Y, Matsumoto M, Fujimura Y, Ikejiri M, Wada H, Miyata T. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. Int J Hematol 2014;100:437-42. [PMID: 25135378 DOI: 10.1007/s12185-014-1655-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
4 Pequeño-Luévano M, Villarreal-Martínez L, Jaime-Pérez JC, Gómez-de-León A, Cantú-Rodríguez OG, González-Llano O, Gómez-Almaguer D. Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases. Hematology 2013;18:233-6. [PMID: 23432850 DOI: 10.1179/1607845412Y.0000000073] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
5 Schaller M, Vogel M, Kentouche K, Lämmle B, Kremer Hovinga JA. The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood 2014;124:3469-79. [DOI: 10.1182/blood-2014-04-561142] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
6 Tong HY, Ye LI, Ye XN, Lu DM, Li Y. Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases. Exp Ther Med 2015;10:2295-8. [PMID: 26668631 DOI: 10.3892/etm.2015.2797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Adv 2020;4:539-45. [PMID: 32045473 DOI: 10.1182/bloodadvances.2019000827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Chen H, Fu A, Wang J, Wu T, Li Z, Tang J, Shen H, Zhu J, Li J, Zhu Q, Qing L. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res. 2017;45:1253-1260. [PMID: 28639502 DOI: 10.1177/0300060517695646] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]